TriSalus Life Sciences, Inc. TLSI Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 85.1%+0.5pp | 84.6%+0.5pp | 84%-0.6pp | 84.7%-0.9pp | 85.6%-0.5pp | |
| Operating margin | -62.4%-2.8pp | -59.7%+18.1pp | -77.7%+8.3pp | -86.1%+12.9pp | -99%+23.9pp | |
| Net margin | -60.9%+26.0pp | -86.9%+11.6pp | -98.4%-11.8pp | -86.6%-1.9pp | -84.7%+17.4pp | |
| EBITDA margin | -61.1%-2.8pp | -58.3%+17.7pp | -76%+8.1pp | -84.1%+12.6pp | -96.7%+23.7pp | |
| Free cash flow margin | -45.2%-3.3pp | -41.9%+13.2pp | -55.1%+26.2pp | -81.3%+29.2pp | -110.5%+29.5pp | |
| Returns | ||||||
| Return on assets | -54.8%+77.5pp | -132.3%-8.5pp | -123.8%-39.3pp | -84.5%+32.5pp | -117%+6.7pp | |
| Efficiency | ||||||
| Asset turnover | 0.9×-0.6× | 1.5×+0.3× | 1.3×+0.3× | 1×-0.4× | 1.4×+0.2× | |
| Inventory turnover | 1.7×-0.3× | 2×+0.2× | 1.8×+0.2× | 1.5×+0.2× | 1.3×+0.1× | |
| Liquidity | ||||||
| Current ratio | 5.8×+3.0× | 2.8×-0.3× | 3.1×-1.0× | 4.1×+1.9× | 2.1×+0.1× | |
| Quick ratio | 5.5×+2.9× | 2.5×-0.2× | 2.8×-0.9× | 3.7×+1.9× | 1.8×+0.2× | |
| Cash ratio | 4.8×+3.0× | 1.8×-0.3× | 2.1×-0.8× | 2.9×+1.7× | 1.1×+0.3× | |
| Leverage | ||||||
| Debt-to-equity | 2.6×— | —— | —— | —— | —— | |
| Debt-to-assets | 0.5×-0.5× | 1×+0.1× | 0.9×+0.1× | 0.8×-0.3× | 1.1×+0.1× | |
| Interest coverage | -4.9×0.0× | -4.9×+1.2× | -6.1×+0.3× | -6.4×+1.0× | -7.4×+4.3× | |
| Per Share | ||||||
| Book value per share | $0.24+127% | -$0.89-44.0% | -$0.62-5.1% | -$0.59+51.0% | -$1.20-17.9% | |
| Valuation | ||||||
| Market capitalization | $279.45M+49.6% | $348.75M+50.4% | $231.88M+16.8% | $198.61M+15.0% | $172.66M+13.0% | |
| Enterprise value | $255.97M+33.6% | $362.4M+50.0% | $241.61M+18.4% | $204.05M+6.8% | $191.01M+14.0% | |
| Price / sales | 6.2×+1.0× | 7.7×+2.0× | 5.8×+0.2× | 5.5×+0.1× | 5.4×+0.2× | |
| Price / book | 22.5×— | —— | —— | —— | —— | |
| EV / sales | 5.9×+0.4× | 8×+2.0× | 6×+0.3× | 5.7×-0.3× | 5.9×+0.3× | |
| Free cash flow yield | -7%+8.1pp | -5.4%+4.1pp | -9.6%+5.2pp | -14.7%+5.8pp | -20.6%+6.4pp | |
| Earnings yield | -9.5%+6.7pp | -11.2%+5.8pp | -17.1%-1.4pp | -15.7%+0.1pp | -15.8%+3.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are TriSalus Life Sciences, Inc.'s profit margins?
- TriSalus Life Sciences, Inc. (TLSI) runs a 85.1% gross margin and a -62.4% operating margin, with a -60.9% net margin.
- Where do TriSalus Life Sciences, Inc.'s ratios come from?
- Every ratio is computed from TriSalus Life Sciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
